增强的皮肤透过输送利拉格卢提德持续肥胖管理的持续肥胖管理
Nipeng Chen1, Zhipeng Zeng1, Haolin Chen1
1PCFM Lab, Guangdong Engineering Technology Research Centre for Functional Biomaterials, School of Materials Science and Engineering, Sun Yat-sen University, Guangzhou 510006, People's Republic of China.
Langmuir : the ACS journal of surfaces and colloids
|May 10, 2025
概括
这项研究提出了一种新的纳米粒子平台,用于通过皮肤输送利拉格化物,克服注射疼痛和针恐惧症. 这种新方法提高了药物透率,并提供了持续的血糖控制和减肥的好处.
科学领域:
- 制药科学 制药科学
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
背景情况:
- 利拉格卢提德是一种GLP-1受体激动剂,对血糖控制和减肥有效,但由于痛苦的皮下注射和针恐惧症而面临粘附问题.
- 通过皮肤递送药物提供了一个非侵入性的,无痛的替代方案,但皮肤障碍挑战了的递送.
- 有效的透皮输送对于改善患者的遵从性和治疗结果至关重要.
研究的目的:
- 开发一种先进的liraglutide通过皮肤传递系统,使用两步纳米粒子制备方法.
- 为了增强利拉格卢提德在糖尿病和肥胖症管理中的通过皮肤透和治疗效果.
- 为了创建一个患者友好的替代品,以皮下注射为liraglutide的管理.
主要方法:
- 使用闪光纳米复杂化 (FNC) 技术将利拉格卢提德封装成由酸 (TA) 和离子 (Al3+) 形成的纳米粒子.
- 纳入了协调和键相互作用,以便在纳米颗粒中稳定地封装利拉格卢提德.
- 用基三甲基化基 (HTCC) 涂覆利拉古胺纳米颗粒,以提高通过皮肤传递的效果.
主要成果:
- 开发的liraglutide纳米颗粒通过皮肤屏障表现出优异的通过皮肤透.
- 实现了持久的低血糖效应,表明有效的血糖控制.
- 在肥胖管理中表现出长期起作用的治疗疗效,展示了持续的药物释放和作用.
结论:
- 两步纳米粒子平台有效地克服了通过皮肤输送的挑战.
- 开发的liraglutide纳米颗粒为皮下注射提供了一个有希望的,非侵入性的替代方案.
- 这种方法具有显著的潜力,可以改善需要利拉格卢提德治疗的患者的坚持和治疗结果.
相关概念视频
Glucagon-like Receptor Agonists
280
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
280
Drug Delivery: Enteral Route
360
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
360
Drugs for Treatment of Constipation-Predominant IBS
124
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
124
Insulin: Dosing Regimen and Adverse Effects
134
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
134
Drug Delivery: Miscellaneous Routes
296
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
296
Drugs for Treatment of Diarrhea-Predominant IBS
131
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
131


